PSC
Principal Exchange-Traded Funds Principal U.S. Small-Cap ETF
stock NASDAQ ETF

The 10% profit on infrastructure doomed Southern Co stock for many years due to the Vogtle build. Southern Co thought they could just past off the ever increasing cost to customers and the PSC stepped in to stop that. Southern Co itself was left with a lot of debt and eventually had to sell off Gulf Power to pay some debt from my understanding of it. That being said if Duke grossly overbuilds or inflates cost of projects to increase their revenue it can ultimately tank the stock if the public commission finds they were negligent. Just a warning from what I researched in the past, and my understanding of it.

They came to the conclusion of that based on revenue, pipeline etc etc. It will be included in the S-4 that will be hopefully here any day now.
I ran the numbers through AI and it agreed that $150M seems like a valuation rooted in the core numbers of what we know so far about the companies that will merge.
There are many examples where biotechs have much higher valuation than cash alone. Especially those who have come a long way with trials, like they have with PSC.

I like how you try to play down the PSC market despite you are a shareholder. The PSC market is predicted to be about $1B+, and there doesnt exist any treatment, and nebokitug have Fast Track from FDA. To most big pharma that is highly lucrative. A lot of the competition have failed their trials and because of that the goal is open.
Chemomab have recently stated they are in ongoing discussions regarding PSC. Thats pretty promising. And there is a $5 CVR for it. I think thats where the discussions are going right now. The trial isnt cheap and there is milestone attached to it. But the revenue stream by far surpass the costs.

The 10% profit on infrastructure doomed Southern Co stock for many years due to the Vogtle build. Southern Co thought they could just past off the ever increasing cost to customers and the PSC stepped in to stop that. Southern Co itself was left with a lot of debt and eventually had to sell off Gulf Power to pay some debt from my understanding of it. That being said if Duke grossly overbuilds or inflates cost of projects to increase their revenue it can ultimately tank the stock if the public commission finds they were negligent. Just a warning from what I researched in the past, and my understanding of it.

They came to the conclusion of that based on revenue, pipeline etc etc. It will be included in the S-4 that will be hopefully here any day now.
I ran the numbers through AI and it agreed that $150M seems like a valuation rooted in the core numbers of what we know so far about the companies that will merge.
There are many examples where biotechs have much higher valuation than cash alone. Especially those who have come a long way with trials, like they have with PSC.

I like how you try to play down the PSC market despite you are a shareholder. The PSC market is predicted to be about $1B+, and there doesnt exist any treatment, and nebokitug have Fast Track from FDA. To most big pharma that is highly lucrative. A lot of the competition have failed their trials and because of that the goal is open.
Chemomab have recently stated they are in ongoing discussions regarding PSC. Thats pretty promising. And there is a $5 CVR for it. I think thats where the discussions are going right now. The trial isnt cheap and there is milestone attached to it. But the revenue stream by far surpass the costs.